All Countries | All Topics

Merck Daily Live Feed

Latest Merck News from Merck Daily Report

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
3,312 of 77,838,009 HEADLINES
  • 27 Jan 22:36 GMT

    2 Stocks to Beat a Recession

    … Growth P/E Ratio Teva Pharmaceutical (Nasdaq: TEVA  ) ***** 0.3 15 … . The long-term view With the pharmaceutical industry driving over the patent … force of generic drug ascendancy will drive Teva Pharmaceutical forward. Generics already … off-patent. The loss by Pfizer, Merck, and AstraZeneca will be the …
  • 27 Jan 21:14 GMT

    Gilead, Celgene Join Big Pharma On M&A Front

    … Medivation Inc MRK * Merck & Co REGN Regeneron Pharmaceutical RHHBY Roche Holding … Sanofi TEVA Teva Pharmaceutical Adr VRTX Vertex Pharmaceuticals WPI Watson Pharmaceuticals * Top-Rated Company … development. Gene mapping is making drug development more precise, targeting patients …
  • 27 Jan 19:13 GMT

    Health Care's Highest Yields

    … of the biggest and highest-yielding drug stocks are declining near attractive … ”). Some of the large, highest-yielding drug companies have also corrected and … .   Click to Enlarge Chart Analysis: Merck & Co. Inc. (MRK) has …
  • 27 Jan 17:18 GMT

    Biogen Idec Explains Company’s Move Away from Venture ...

    … million each (Johnson & Johnson, Merck & Co., and Pfizer), then … in October joined with Portola Pharmaceuticals to develop and commercialize oral … inflammatory diseases. And with Isis Pharmaceuticals, Biogen Idec announced January 4 … option to license Isis’ antisense drug ISIS-SMNRx, a treatment for spinal …
  • 27 Jan 17:16 GMT

    Trius Therapeutics: Weakness Presents Opportunity

    … , daptomycin (Cubicin) by Cubist Pharmaceuticals (CBST), and linezolid or … myelosuppression and significant, possibly fatal drug interactions. It is known … by GlaxoSmithKline Rizatriptan (Maxalt) by Merck Life-threatening serotonin syndrome •Agitation • …
  • 27 Jan 17:16 GMT

    Vertex Pharmaceuticals Could See Huge Long-Term Gains

    … Janssen Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Cystic Fibrosis Foundation Therapeutics Incorporated, Merck … is headquartered in Cambridge, Massachusetts. Drug Pipeline Telaprevir (VX-950), treatment of … an acquisition target for mega pharmas like Bristol-Meyers (BMY) and Pfizer …
  • 27 Jan 16:23 GMT

    Research and Markets: Nanotechnology in Drug Delivery 2011-...

    … breaks down the current nanotechnology drug delivery market into geographic markets … . Merck Sharp & Dohme Corp. Nano Interface Technology, Inc Novartis Pharmaceuticals Novavax, Inc. NUCRYST Pharmaceuticals Corp. PAR Pharmaceutical, Inc. Particle …
  • 27 Jan 16:22 GMT

    Research and Markets: Nanotechnology in Drug Delivery 2011-...

    … breaks down the current nanotechnology drug delivery market into geographic markets … . Merck Sharp & Dohme Corp. Nano Interface Technology, Inc Novartis Pharmaceuticals Novavax, Inc. NUCRYST Pharmaceuticals Corp. PAR Pharmaceutical, Inc. Particle …
  • 27 Jan 15:32 GMT

    Research and Markets: Patent Expiry Strategies of Big Pharma

    … . This report analyzes the strategies pharmaceutical companies are employing before and … stronger patent portfolio in the pharmaceutical industry by examining the many … drug development increasing, it is becoming a struggle for even major pharmaceutical … plc Eli Lilly & Co. Merck & Co., Inc. Abbott Laboratories …
  • 27 Jan 15:11 GMT

    New drugs may lift pharma revenues in 2012

    … multi-billion dollar categories will help pharmaceutical companies offset patent expirations and … between Johnson & Johnson and Merck & Co. in the nearly … . Teva Pharmaceuticals Ltd. will likely suffer as its blockbuster drug Copaxone loses …
  • 27 Jan 13:38 GMT

    What Pharma and Finance Marketers Can Teach One Another

    … . Rockoff reports that several drug companies (including GlaxoSmithKline, Merck& Co and … improved and drug sales are rising. With this shift, big pharma has … at a rapid pace. Endorsement-Marketing. Pharmaceutical companies are experts at endorsement-marketing …
  • 26 Jan 23:18 GMT

    Merck uses R&D arm to grow flagship drugs

    … domestic sales, Merck, the Indian arm of $12-billion German pharma giant Merck, is …
  • 26 Jan 21:27 GMT

    Merck urges more R&D from state

    … and development to help its pharmaceutical industry grow, especially once the … director of Merck Thailand, a unit of the German pharmaceutical and chemical … and Malaysia, respectively. The Vietnamese pharmaceutical market is growing a lot … lot of restrictions in the pharmaceutical field that makes further investments …
  • 26 Jan 20:12 GMT

    Real estate gets a shot in the arm by pharma

    … buying Madison-headquartered drug firm Wyeth for $68 billion, German giant Merck agreed … (HBS Pharma), Bharuch  Jubilant Organosys, Bharuch  Cadila Pharma SEZ, Surat  Dishman Pharma, Ahmedabad Source: Gujarat Industrial Development Corporation (GIDC) Pharma …
  • 26 Jan 17:45 GMT

    Novartis to Settle Drug Sales Rep Overtime Claims for $99 ...

    Novartis Pharmaceuticals Corp. is set to pay … ,” Andre Wyss, president of Novartis Pharmaceuticals, a unit of Novartis AG … practice for drug makers to avoid paying overtime for pharmaceutical sales representatives … Co. and a unit of Merck & Co.
  • 26 Jan 16:27 GMT

    Did You Fall for Big Pharma's Bone Scam?

    … before Fosamax, Merck's blockbuster bone drug, was approved, Merck began marketing … scans were so lucrative to drug companies, when their Medicare-reimbursement became … the biggest bone drug patents are expired so the drug companies don …
  • 26 Jan 12:38 GMT

    Licensing deals down as pharma tightens belt

    … report from UK advisory firm PharmaVentures. According to a review of … Pharmaceutical, a Chinese manufacturer of generic injectable antibiotics, while other big pharma … and Merck & Co/Sun Pharmaceutical Industries alliances in India. Fintan Walton, PharmaVentures …
  • 26 Jan 11:50 GMT

    Merck Serono’s Rebif approved in EU for early-stage MS

    … study, which showed that Merck’s drug could delay the onset of … and 62 per cent for Merck’s drug. “MS has an initial … , head of global drug development and medical at Merck Serono. “Throughout the … : 26/01/2012 Content Area: Pharmaceutical industry articles Article type: Healthcare …
  • 25 Jan 19:06 GMT

    Significantly Favorable Risk/Reward For Abbott, Merck

    … Street is currently bullish about Merck & Co. (MRK), it continues … least volatility. Mylan (MYL) and Merck, meanwhile, trade at a respective … will be spinning off its pharmaceutical business. In light of complications … development have been overshadowed by Merck's reputation for having …
  • 25 Jan 19:06 GMT

    4 Pharmaceutical Companies Facing Huge Patent Cliff Hurdles

    … exceptions under the Hatch-Waxman Act. Pharmaceutical companies which enjoy monopoly pricing … Singulair. Merck is expected to find 43% of its 2010 pharmaceutical sales exposed to patent expiry risk by 2013. Merck will … the acquisition of another pharmaceutical company for its drug pipeline. It is …
  • 25 Jan 17:20 GMT

    FDA label shows Merck cholesterol drug helps heart

    … prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to … with doctors. Merck had asked the Food and Drug Administration to approve … percent dip in the Arca Pharmaceuticals Index. Vytorin pairs a new … , or ezetimibe, with Merck's older statin drug Zocor, or simvastatin …
Tools